metabolic dysfunction-associated fatty liver disease
Conditions
Interventions
Dietary intervention group:The patients in this group were given a light vegetarian diet intervention, and pictures were taken before and after three meals, and the specific diet types were described
Fruits (except durian, mango, lychee, etc.)
Daily can drink porridge: millet based, Job's tears, red bean porridge, 1 ~ 2 times a day
Exercise intervention group:Exercise intervention was performed in this group of patients, and video recording was performed for archiving. Exercise strictly in accordance with the following exercise
Diet and exercise combined intervention group:In this group of patients, light vegetarian diet intervention and exercise intervention were carried out simultaneously. The diet pattern and exercise pre
Healthy control group:No special intervention for patients
Healthy group on time-restricted diet alone:Eating time is set within 8 hours per day, and there is no restriction on food types
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) patients with the diagnostic criteria of MAFLD (2) patients at age 18-65; (3) individuals with body mass index (BMI) between 18.5 and 35; (4) Volunteer to participate in the study and sign the informed consent
Exclusion criteria
Exclusion criteria: (1) Patients who have progressed to the decompensated stage of cirrhosis; (2) Women in the pregnancy or breastfeeding period, allergic people; (3) Patients with other serious brain, heart, lung, kidney, blood system, connective tissue and muscle system, malignant tumor diseases and mental diseases in addition to hypertension, diabetes, hyperlipidemia; (4) Patients with severe metabolic disorders, including uncontrolled hypertension (diastolic blood pressure =100 mmHg or systolic blood pressure =180 mmHg), type I diabetes mellitus, type II diabetes mellitus with brain, eye, kidney complications, type II diabetes mellitus with poor blood glucose control and HBA1c > 10%; (5) People who have used any other drug within 3 months that affects liver function, causes hepatic steatosis, or may have an impact on this study (including tamoxifen, ethamiodarone, sodium valproate, methotrexate, glucocorticoids, probiotics, amiodarone, olazepine).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HFC;liver function;Blood lipid;Weight change; | — |
Secondary
| Measure | Time frame |
|---|---|
| Waist circumference;blood sugar;blood pressure;hs-CRP;Oxidative stress indicators; | — |
Countries
CHINA
Contacts
Public ContactShukun Yao
Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, China
Outcome results
None listed